J
Jane M. Andrews
Researcher at Royal Adelaide Hospital
Publications - 329
Citations - 14638
Jane M. Andrews is an academic researcher from Royal Adelaide Hospital. The author has contributed to research in topics: Inflammatory bowel disease & Medicine. The author has an hindex of 48, co-authored 298 publications receiving 12270 citations. Previous affiliations of Jane M. Andrews include St. Vincent's Health System & Health Science University.
Papers
More filters
Journal ArticleDOI
General practitioners' knowledge of and attitudes to inflammatory bowel disease
TL;DR: GPs' attitudes to and knowledge of IBD were assessed, with a focus on general practitioners' first point of contact for initial symptoms and flares.
Journal ArticleDOI
Perspectives of paediatric and adult gastroenterologists on transfer and transition care of adolescents with inflammatory bowel disease
Emily K Wright,Joanne Williams,Joanne Williams,Jane M. Andrews,Andrew S. Day,Richard B. Gearry,Peter A. Bampton,David J. Moore,Daniel A. Lemberg,R. Ravikumaran,J.M. Wilson,Peter Lewindon,Graham L. Radford-Smith,Jerrold F. Rosenbaum,Anthony G. Catto-Smith,Paul V. Desmond,William Connell,Donald J. S. Cameron,George Alex,Sally Bell,P. De Cruz +20 more
TL;DR: Programmes specific to inflammatory bowel disease (IBD) that facilitate transition from paediatric to adult care are currently lacking.
Journal ArticleDOI
Obesity in Inflammatory Bowel Disease: Gains in Adiposity despite High Prevalence of Myopenia and Osteopenia.
Robert V Bryant,Christopher G. Schultz,Soong Ooi,Charlotte Goess,Samuel P Costello,Andrew D. Vincent,Scott Schoeman,Amanda Lim,Francis Dylan Bartholomeusz,Simon Travis,Jane M. Andrews,Jane M. Andrews +11 more
TL;DR: Increasing rates of obesity in patients with IBD coincide with decreases in lean muscle mass over time, while high rates of osteopenia remain stable, and these previously undocumented issues warrant attention in routine care to prevent avoidable morbidity.
Journal ArticleDOI
Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis
Ian C. Lawrance,Angela Baird,Daniel Lightower,Graham L. Radford-Smith,Jane M. Andrews,Susan J. Connor +5 more
TL;DR: Rectal tacrolimus was more effective than placebo for induction of a clinical response, clinical remission, and mucosal healing in resistant ulcerative proctitis.
Journal ArticleDOI
Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
A. James M. Daveson,Hooi C. Ee,Jane M. Andrews,Tim King,Kaela E. Goldstein,John L. Dzuris,James MacDougall,Leslie J. Williams,Anita Treohan,Michael P. Cooreman,Robert P. Anderson +10 more
TL;DR: The aim was to test whether stepwise dose escalation attenuated the first dose effect of Nexvax2 in celiac disease patients, and the primary outcome was the number of adverse events and percentage of participants with adverse events during the treatment period.